Literature DB >> 32162838

Elective Termination of Pregnancy in Autoimmune Rheumatic Diseases: Experience From Two Databases.

Michael D Lockshin1, Marta Guerra1, Jane E Salmon1.   

Abstract

OBJECTIVE: To provide reference data regarding the frequency and safety of elective termination of pregnancy in women with autoimmune rheumatic diseases followed up in 2 referral databases.
METHODS: Two large databases, one from an autoimmune rheumatic disease referral clinical practice with a known interest in pregnancy (the Barbara Volcker Center for Women and Rheumatic Disease [BVC]), and one from an observational study of systemic lupus erythematosus- and antiphospholipid antibody-associated pregnancies (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus [PROMISSE]), were interrogated for histories of prior elective termination of pregnancy and complications related to incident pregnancy termination.
RESULTS: Of women who had had prior pregnancies, 21.7% of 1,307 in the BVC database and 25.3% of 297 in the PROMISSE database gave histories of 1-5 prior elective terminations of pregnancy; BVC patients reported no flares or hospitalizable complications due to pregnancy termination. Of 674 incident pregnancies, termination for fetal or maternal reasons was recommended for 15 (2%); of these, 2 fetuses died before the procedure was carried out and 1 woman declined termination and, though gravely ill, successfully delivered. She died of cardiomyopathy 3 years later.
CONCLUSION: Many patients with autoimmune rheumatic disease undergo elective termination of pregnancy; few report complications. In medically indicated termination of pregnancy, there are no adverse signals of unusual complications or disease flare.
© 2020, American College of Rheumatology.

Entities:  

Mesh:

Year:  2020        PMID: 32162838      PMCID: PMC7486237          DOI: 10.1002/art.41249

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  6 in total

1.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

2.  Executive summary: Reproductive Services for Women at High Risk for Maternal Mortality Workshop, February 11-12, 2019, Las Vegas, Nevada.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2019-06-19       Impact factor: 8.661

3.  Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.

Authors:  Jill P Buyon; Mimi Y Kim; Marta M Guerra; Carl A Laskin; Michelle Petri; Michael D Lockshin; Lisa Sammaritano; D Ware Branch; T Flint Porter; Allen Sawitzke; Joan T Merrill; Mary D Stephenson; Elisabeth Cohn; Lamya Garabet; Jane E Salmon
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

4.  2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

Authors:  Lisa R Sammaritano; Bonnie L Bermas; Eliza E Chakravarty; Christina Chambers; Megan E B Clowse; Michael D Lockshin; Wendy Marder; Gordon Guyatt; D Ware Branch; Jill Buyon; Lisa Christopher-Stine; Rachelle Crow-Hercher; John Cush; Maurice Druzin; Arthur Kavanaugh; Carl A Laskin; Lauren Plante; Jane Salmon; Julia Simard; Emily C Somers; Virginia Steen; Sara K Tedeschi; Evelyne Vinet; C Whitney White; Jinoos Yazdany; Medha Barbhaiya; Brittany Bettendorf; Amanda Eudy; Arundathi Jayatilleke; Amit Aakash Shah; Nancy Sullivan; Laura L Tarter; Mehret Birru Talabi; Marat Turgunbaev; Amy Turner; Kristen E D'Anci
Journal:  Arthritis Rheumatol       Date:  2020-02-23       Impact factor: 10.995

5.  Abortion Surveillance - United States, 2015.

Authors:  Tara C Jatlaoui; Maegan E Boutot; Michele G Mandel; Maura K Whiteman; Angeline Ti; Emily Petersen; Karen Pazol
Journal:  MMWR Surveill Summ       Date:  2018-11-23

6.  Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.

Authors:  Cecile M Yelnik; Carl A Laskin; T Flint Porter; D Ware Branch; Jill P Buyon; Marta M Guerra; Michael D Lockshin; Michelle Petri; Joan T Merrill; Lisa R Sammaritano; Mimi Y Kim; Jane E Salmon
Journal:  Lupus Sci Med       Date:  2016-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.